DTRMWXHS-12

DRUG3 trials

Sponsors

Zhejiang DTRM Biopharma

Conditions

B-Cell LymphomaB-cell LymphomasChronic Lymphocytic LeukemiaMantle Cell Lymphoma

Phase 1

Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas

CompletedNCT02891590

Zhejiang DTRM BiopharmaB-cell Lymphomas, Chronic Lymphocytic Leukemia

Start: 2016-09-30End: 2019-02-28Updated: 2020-04-14

Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas

CompletedNCT02900716

Zhejiang DTRM BiopharmaB-Cell Lymphoma, Chronic Lymphocytic Leukemia

Start: 2016-09-30End: 2020-11-23Updated: 2020-11-27

BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma

CompletedNCT03836768

Zhejiang DTRM BiopharmaMantle Cell Lymphoma

Start: 2019-01-11End: 2021-11-17Updated: 2023-02-15

Related Papers

A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma

Blood2020-11-0413 citations

A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas

Blood2019-11-139 citations

Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality

Blood2018-11-292 citations

A phase Ia/Ib study of a novel BTK inhibitor, DTRMWXHS-12 (DTRM-12), and combination products, with everolimus and pomalidomide, in pts with CLL or other B-cell lymphomas.

Journal of Clinical Oncology2017-05-202 citations